

# PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**Bracco et al.**

Serial No.: **08/930,480**

Filed: **January 21, 1998**

Title: **Conditional Expression System**



Examiner: **McKelvey, T.**

Art Unit: **1636**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

17 May 2000  
Date of Deposit  
Selma L. Wetherill  
Signature

### RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed **December 20, 1999** ("the Notice"), Applicants submit herewith the following documents required under 37 CFR 1.821 through 1.825:

1. A copy of the Notice;
2. A Submission of Computer Readable Sequence Listing with attached copy of the Sequence Listing in computer readable form and in paper form.

Applicants respectfully submit that they have now complied with the requirements of 37 CFR 1.821 through 1.825. Please contact the undersigned attorney for Applicants if there are any additional questions on this matter.

Respectfully submitted,

Karen I. Krupen  
Karen I. Krupen, Reg. #34,647  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626  
Docket No. ST95021-US